CA-CHARGEPOINT-HOLDINGS
5.10.2022 09:01:38 CEST | Business Wire | Press release
ChargePoint Holdings, Inc. (NYSE: CHPT), a leading electric vehicle (EV) charging network, today announced the launch of the CP6000, ChargePoint’s most flexible and serviceable global AC EV charging solution now available for vehicles of all types and sizes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005038/en/
(Photo: Business Wire)
Designed for the needs of the European market, the CP6000 is a complete charging solution for businesses and fleets that want to confidently and efficiently prepare for the future of electric mobility. Seamlessly integrating network software, station hardware and customer support, the CP6000 is designed to prepare businesses of all kinds across the globe for the next wave of EV adoption. The CP6000 is designed for scalability, flexibility, reliability, and a best-in-class driver experience, and offers reliable AC charging for 1 or 3 phase power at an adaptable output of 3.7 to 22kw per port.
“ChargePoint’s mission is to make the transition to electric mobility simple. As the result of ChargePoint’s experience shaping the charging industry over the past 15 years, we understand what is critical to station owners and drivers, including effortless charging experiences, scalable design, quality products and excellent service,” stated ChargePoint Chief Product Officer, Bill Loewenthal. “EV charging needs are universal, even if what and how we drive varies by geography. The CP6000 has been designed across our R&D facilities in North America and Europe to cater to the charging needs of businesses, fleets and EV drivers. Built on our decade-plus of experience serving EV drivers and all types of organisations, CP6000 has what businesses need to be part of the future of electric mobility.”
Superior driver experience
Whether charging is for employees, customers, visitors or a fleet, the driver is at the centre of it all, which is why the driver is at the centre of the CP6000 design. The top-rated ChargePoint app has over 200,000 active places to charge on its network globally, as well an additional 355,000 public places to charge through roaming integrations with other major networks. ChargePoint driver support is available in multiple languages, ensuring drivers across Europe receive the best experience possible. The addition of the CP6000 to ChargePoint’s network ensures drivers are easily able to find, use and pay for the charge they need, in the language and currency they prefer.
“The new CP6000 series is a great addition to an already strong contingent of reliable, software driven hardware we offer our clients,” stated Bruce Galliford, CEO at RAW Charging, one of the first customers to receive the new technology. “When ChargePoint expanded to Europe, we saw a company with the longevity, customer base, engineering prowess and experience to be a fit with our vision. Leaving the technology to ChargePoint, we can focus on deployment. We have more projects coming for Aviva Investors, Greene King, McArthurGlen and other customers. We’re currently planning strategic expansion across Europe working with organisations that have a portfolio of sites across the continent. This year we’ll be putting in four new sites per working day, and when you’re doing that, you want it to work flexibly and at scale.”
Part of ChargePoint's unified software platform
The CP6000 works seamlessly with ChargePoint’s software platform, which offers real-time visibility into revenue, energy costs and driver details, complete control over pricing and driver access, and actionable reporting with over 35 pre-built charts and reports. ChargePoint’s software also includes robust power management tools to automatically reduce energy costs, on-station video messages, and over 40 turnkey API integrations. The CP6000 is also fully compliant with Open Charge Point Protocol (OCPP) 2.01, the latest version of the open standard. Together, these features make it easy for customers to manage their charging program, reduce costs, improve utilisation, and prepare for the future.
Built for the future of electrification
ChargePoint believes demand for EV charging is poised for rapid growth. The CP6000 series’ modular design and forward-thinking technology supports flexible configurations and easy upgrades, making it the robust solution for scaling EV charging availability and maximising station value. It can be customised into dozens of configurations for multiple use cases or regions, offering options on sockets, cable management, branding, display, shuttering and more. This modularity allows the CP6000 to more easily support field replacements and service, while also offering advanced sensors for enhanced diagnostics and support.
The CP6000 has also been designed to operate on Europe's variety of power grids and regulations. For example, the CP6000 meets the UK government's requirements for contactless payment capabilities for all AC stations of 7.1kW and above.
The CP6000 is now available to order across dozens of ChargePoint operating countries. To learn more about deploying the CP6000 across your business, contact your ChargePoint sales representative or distributor.
About ChargePoint
ChargePoint is creating a new fueling network to move people and goods on electricity. Since 2007, ChargePoint has been committed to making it easy for businesses and drivers to go electric with one of the largest EV charging networks and a comprehensive portfolio of charging solutions available today. The ChargePoint cloud-based subscription platform and software-defined charging hardware are designed to include options for every charging scenario from home and multifamily to workplace, parking, hospitality, retail and transport fleets of all types. Today, one ChargePoint account provides access to hundreds of thousands of places to charge in North America and Europe. To date, more than 133 million charging sessions have been delivered, with drivers plugging into the ChargePoint network on average every second. For more information, visit the ChargePoint pressroom, the ChargePoint Investor Relations site, or contact ChargePoint’s North American or European press offices or Investor Relations.
CHPT-IR
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005038/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
